AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by Liberum Capital in a report released on Tuesday. They presently have a GBX 5,200 ($67.88) price target on the biopharmaceutical company’s stock. Liberum Capital’s target price points to a potential upside of 3.13% from the stock’s previous close.
Other analysts have also issued reports about the stock. Bryan, Garnier & Co reiterated a “buy” rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Morgan Stanley reiterated an “overweight” rating and set a GBX 5,000 ($65.27) target price on shares of AstraZeneca plc in a report on Monday, July 11th. Credit Suisse Group AG reiterated an “underperform” rating and set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc in a report on Monday, June 27th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc and gave the stock a “sell” rating in a report on Tuesday. Finally, Jefferies Group increased their target price on shares of AstraZeneca plc from GBX 4,100 ($53.52) to GBX 4,450 ($58.09) and gave the stock a “hold” rating in a report on Thursday, June 30th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca plc currently has a consensus rating of “Hold” and an average target price of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5042.00 on Tuesday. The firm’s market cap is GBX 63.78 billion. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s 50-day moving average price is GBX 5,006.61 and its 200-day moving average price is GBX 4,427.08.
The business also recently announced a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.